Evaluation of effect of sivelestat administration on postoperative course of patients with thoracic esophageal cancer who underwent trans-thoracic esophagectomy.

Evaluation of effect of sivelestat administration on postoperative course of patients with thoracic esophageal cancer who underwent trans-thoracic esophagectomy. - Sivelestat on esophageal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000557

Enrollment

Registered

2007-01-01

Start date

2006-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Post operative administrations of sivelestat (day 0- day 4) Control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Thoracic esophageal cancer. Trans-thoracic esophagectomy along with lymphadenectomy.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Postoperative complication Postoperative inflammatory parameters *Recurrent disease	—

Countries

Japan

Contacts

Public ContactHideaki Shimada

Chiba University Graduate School of Medicine Frontier Surgery

043-226-2110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026